LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Search

iRhythm Technologies Inc

Закрыт

СекторЗдравоохранение

136.98 -2.21

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

135.42

Макс.

140.82

Ключевые показатели

By Trading Economics

Доход

9M

-5.2M

Продажи

6.2M

193M

Рентабельность продаж

-2.702

Сотрудники

2,000

EBITDA

7.7M

2.4M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+50.35% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

30 апр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-1.2B

4.6B

Предыдущая цена открытия

139.19

Предыдущая цена закрытия

136.98

Новостные настроения

By Acuity

50%

50%

149 / 351 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

iRhythm Technologies Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 февр. 2026 г., 22:53 UTC

Приобретения, слияния, поглощения

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 февр. 2026 г., 22:36 UTC

Отчет

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 февр. 2026 г., 22:32 UTC

Отчет

Woodside Energy Fiscal Year Net Profit Falls 24%

23 февр. 2026 г., 23:58 UTC

Обсуждения рынка
Отчет

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 февр. 2026 г., 23:58 UTC

Обсуждения рынка
Отчет

Global Energy Roundup: Market Talk

23 февр. 2026 г., 23:47 UTC

Обсуждения рынка

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 февр. 2026 г., 23:43 UTC

Обсуждения рынка

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 февр. 2026 г., 23:41 UTC

Приобретения, слияния, поглощения

Crescent Capital Partners Owns 53% of ClearView Wealth

23 февр. 2026 г., 23:40 UTC

Приобретения, слияния, поглощения

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 февр. 2026 г., 23:40 UTC

Приобретения, слияния, поглощения

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 февр. 2026 г., 23:40 UTC

Обсуждения рынка

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 февр. 2026 г., 23:40 UTC

Приобретения, слияния, поглощения

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 февр. 2026 г., 23:39 UTC

Приобретения, слияния, поглощения

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 февр. 2026 г., 23:31 UTC

Отчет

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 февр. 2026 г., 23:31 UTC

Отчет

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 февр. 2026 г., 23:28 UTC

Отчет

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 февр. 2026 г., 23:28 UTC

Отчет

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 февр. 2026 г., 23:28 UTC

Отчет

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 февр. 2026 г., 23:27 UTC

Отчет

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 февр. 2026 г., 23:24 UTC

Обсуждения рынка

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 февр. 2026 г., 22:38 UTC

Приобретения, слияния, поглощения

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 февр. 2026 г., 22:31 UTC

Отчет

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 февр. 2026 г., 22:24 UTC

Отчет

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy FY Underlying Ebitda A$700.9 Million

23 февр. 2026 г., 22:22 UTC

Отчет

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 февр. 2026 г., 22:21 UTC

Отчет

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 февр. 2026 г., 22:21 UTC

Отчет

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 февр. 2026 г., 22:20 UTC

Отчет

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Сравнение c конкурентами

Изменение цены

iRhythm Technologies Inc Прогноз

Целевая цена

By TipRanks

50.35% рост

Прогноз на 12 месяцев

Средняя 212.33 USD  50.35%

Максимум 254 USD

Минимум 184 USD

Основано на мнении 13 аналитиков Wall Street, спрогнозировавших целевые цены для iRhythm Technologies Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

13 ratings

12

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

104.78 / 137.91Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Strong Bullish Evidence

Долгосрочная

Bullish Evidence

Настроения

By Acuity

149 / 351Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании iRhythm Technologies Inc

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
help-icon Live chat